It is not every day that you see crude oil prices moving higher and the Asian markets, including India, also inching higher. Now, as an inv...

Usually, official talks are mere formalities – meetings to ink things that have already been agreed upon. The one scheduled between the US ...

With Israel refusing to play ball and Iran maintaining its vice-like hold on the Strait of Hormuz, the ceasefire declared by US President T...

The market is again abuzz with the possibility of peace in the Gulf. This has, however, happened in the past. There is, thus, no point in g...

The rising stock price of a company does not mean that the business is strong. And a falling stock price does not mean that the business is...

Normally, one-day moves of the indices should never be taken as a sign of what is in store for the market. However, there are times when ev...

Here’s a lesson from history: For a long-term investor, buying in a correcting market is mostly an opportunity. The operative part, of cour...

When it comes to large-caps, we think of Reliance, TCS, L&T or Infosys. The fact, however, is that these are not large-caps – they are mega...

At a time when the Nifty and Sensex are trading with cuts in excess of 1%, talking of buying stocks may not appear quite right. But correct...

There are some sectors which have witnessed something which can be called “second inning”. Which is that in the last two decades, they did ...

There are many textbook definitions of the word “ moat”. But what it means in simple terms is that there has to be something in a business ...

There cannot be any doubt about volatility on the street, both as reflected by advance decline ratio or the kind of movement we see in nift...

While all pharma companies get classified into one sector they are very different at molecular level. Each company has its own operating ma...

Dozens of Indian drugmakers have launched cut-price versions of teneligliptin, a new generation medicine for type 2 diabetes patients.

Mankind Pharma will invest Rs 200 crore to open two manufacturing plants in the country by the middle of 2016 as part of its expansion plan...

India's anti-diabetic market is one of the fastest growing therapy segments, with a growth exceeding 25% at Rs 7638 crore, according to the...

Mankind Pharma has launched an anti-diabetic product 'Dynaglipt' targeting the middle class and rural diabetic patients.